glenmark pharma
Jump to
1211 Results Found
  • Glenmark Standalone December 2020 Net Sales at Rs 1,972.48 crore, up 8.6% Y-o-Y Feb 16, 2021 01:11 PM IST

    Glenmark Standalone December 2020 Net Sales at Rs 1,972.48 crore, up 8.6% Y-o-Y

  • Glenmark Pharma gets USFDA nod for seizure treatment drug Feb 03, 2021 12:32 PM IST

    Glenmark Pharma gets USFDA nod for seizure treatment drug

    The approved product is a generic version of Qudexy XR Capsules of Upsher-Smith Laboratories, LLC.

  • Glenmark Pharma share price up 2% on final approval from USFDA for Topiramate Extended-Release Capsules Feb 03, 2021 10:44 AM IST

    Glenmark Pharma share price up 2% on final approval from USFDA for Topiramate Extended-Release Capsules

    The share touched its 52-week high Rs 572.70 and 52-week low Rs 168 on 22 June, 2020 and 13 March, 2020, respectively.

  • Glenmark Pharma share price rises on US FDA final approval Jan 28, 2021 11:50 AM IST

    Glenmark Pharma share price rises on US FDA final approval

    The share touched its 52-week high Rs 572.70 and 52-week low Rs 168 on 22 June, 2020 and 13 March, 2020, respectively.

  • Glenmark Pharma gets USFDA nod for nervous system stimulant drug Jan 28, 2021 10:40 AM IST

    Glenmark Pharma gets USFDA nod for nervous system stimulant drug

    The approved product is a generic version of Evekeo tablets of Arbor Pharmaceuticals LLC.

  • Glenmark Pharma shares rise on licensing agreement with Menarini Dec 23, 2020 11:14 AM IST

    Glenmark Pharma shares rise on licensing agreement with Menarini

    Ryaltris and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.

  • Glenmark Pharma share price rises nearly 3% on tentative approval from USFDA Dec 21, 2020 11:33 AM IST

    Glenmark Pharma share price rises nearly 3% on tentative approval from USFDA

    The share touched its 52-week high of Rs 572.70 and 52-week low of Rs 168 on 22 June, 2020 and 13 March, 2020, respectively.

  • Glenmark Pharma gets tentative nod from USFDA for anticoagulant drug Dec 21, 2020 11:11 AM IST

    Glenmark Pharma gets tentative nod from USFDA for anticoagulant drug

    The approved product is a generic version of Boehringer Ingelheim Pharmaceuticals’ Pradaxa capsules. Pradaxa is used to prevent blood clots from forming because of certain irregular heart rhythm.

  • Glenmark Pharma share price gains on tentative USFDA nod for kidney cancer drug Dec 01, 2020 12:28 PM IST

    Glenmark Pharma share price gains on tentative USFDA nod for kidney cancer drug

    The company has received FDA's tentative nod for Axitinib tablets in the strength of 1mg and 5 mg.

  • Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug Dec 01, 2020 11:41 AM IST

    Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug

    The tentatively approved product is the generic version of Inlyta tablets of PF Prism CV.

  • Glenmark Pharma gets USFDA nod to market drug for relapsing multiple sclerosis Oct 07, 2020 11:50 AM IST

    Glenmark Pharma gets USFDA nod to market drug for relapsing multiple sclerosis

    The approved product is a generic version of Biogen Inc’s Tecfidera delayed-release capsules.

  • Glenmark Pharma share price rises on final USFDA approval for a generic Oct 07, 2020 09:52 AM IST

    Glenmark Pharma share price rises on final USFDA approval for a generic

    Glenmark Pharma has been granted final approval by the USFDA for Dimethyl Fumarate Delayed-Release Capsules.

  • Quant Pick - Glenmark Pharma: ICICI Direct Sep 11, 2020 04:43 PM IST

    Quant Pick - Glenmark Pharma: ICICI Direct

    According to ICICI Direct, The pharma space has shown significant resilience in the last couple of weeks amid broader market volatility.

  • Buy Glenmark Pharma; target of Rs 576 KRChoksey Aug 21, 2020 02:06 PM IST

    Buy Glenmark Pharma; target of Rs 576 KRChoksey

    KRChoksey is bullish on Glenmark Pharma has recommended buy rating on the stock with a target price of Rs 576 in its research report dated August 20, 2020.

  • Buy Glenmark Pharma; target of Rs 575: Emkay Global Financial Aug 20, 2020 01:37 PM IST

    Buy Glenmark Pharma; target of Rs 575: Emkay Global Financial

    Emkay Global Financial is bullish on Glenmark Pharma has recommended buy rating on the stock with a target price of Rs 575 in its research report dated August 17, 2020.

  • Neutral Glenmark Pharma; target of Rs 495: Motilal Oswal Aug 20, 2020 01:36 PM IST

    Neutral Glenmark Pharma; target of Rs 495: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Glenmark Pharma with a target price of Rs 495 in its research report dated August 17, 2020.

  • Glenmark Pharma shares trade lower after CLSA retains 'sell' Aug 18, 2020 10:08 AM IST

    Glenmark Pharma shares trade lower after CLSA retains 'sell'

    The global research firm has maintained sell call on the stock and has raised target to Rs 470 from Rs 420 per share.

  • Glenmark Consolidated June 2020 Net Sales at Rs 2,344.79 crore, up 0.94% Y-o-Y Aug 17, 2020 10:55 AM IST

    Glenmark Consolidated June 2020 Net Sales at Rs 2,344.79 crore, up 0.94% Y-o-Y

  • Glenmark Standalone June 2020 Net Sales at Rs 1,682.92 crore, up 12.29% Y-o-Y Aug 17, 2020 10:44 AM IST

    Glenmark Standalone June 2020 Net Sales at Rs 1,682.92 crore, up 12.29% Y-o-Y

  • Glenmark Pharma shares gain after Q1 profit jumps two-fold to Rs 254 crore Aug 17, 2020 10:19 AM IST

    Glenmark Pharma shares gain after Q1 profit jumps two-fold to Rs 254 crore

    The company's formulation sales in the domestic market in the first quarter rose to Rs 779.89 crore from Rs 752.21 crore in the same period of previous fiscal, up 3.68 percent.

  • DCGI seeks clarification from Glenmark Pharma on its claim of FabiFlu use for COVID-19 patients with comorbidities Jul 19, 2020 08:30 PM IST

    DCGI seeks clarification from Glenmark Pharma on its claim of FabiFlu use for COVID-19 patients with comorbidities

    Glenmark Pharmaceuticals had on July 13 said it has cut the price of its antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 by 27 percent to Rs 75 per tablet.

  • Neutral Glenmark Pharma; target of Rs 430: Motilal Oswal Jul 01, 2020 11:02 AM IST

    Neutral Glenmark Pharma; target of Rs 430: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Glenmark Pharma with a target price of Rs 430 in its research report dated June 29, 2020.

  • Glenmark Pharma share price tumbles 5% on price-fixing allegations in US Jul 01, 2020 10:37 AM IST

    Glenmark Pharma share price tumbles 5% on price-fixing allegations in US

    The charge was filed in US District Court in Philadelphia. The price-fixing conspiracy allegedly took place from 2013 to 2015 and caused a loss to victims of at least $200 million, according to the department.

  • Buy Glenmark Pharma; target of Rs 526: Emkay Global Financial Jul 01, 2020 10:31 AM IST

    Buy Glenmark Pharma; target of Rs 526: Emkay Global Financial

    Emkay Global Financial is bullish on Glenmark Pharma has recommended buy rating on the stock with a target price of Rs 526 in its research report dated June 29, 2020.

  • Glenmark Standalone March 2020 Net Sales at Rs 1,607.73 crore, up 1.29% Y-o-Y Jun 29, 2020 11:11 AM IST

    Glenmark Standalone March 2020 Net Sales at Rs 1,607.73 crore, up 1.29% Y-o-Y

Sections